The Europe Cancer Diagnostics Market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% during the forecast period 2024–2031. The Europe cancer diagnostics market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, increasing investments and funding for cancer research, rising awareness about cancer, and advancements in cancer diagnostics technology. However, the high cost of imaging systems restrains the growth of this market.
Furthermore, supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market. However, the lack of skilled professionals and insufficiencies in the national implementation of cancer screening programs are major challenges impacting the market growth.
The burden of cancer is growing in Europe. According to GLOBOCAN 2020, cancer incidence is expected to increase from 4.4 million in 2020 to 5.1 million in 2035. Early detection is extremely important in reducing mortality, improving patients’ chances of survival, and saving on treatment costs. Various methods are used to detect cancer. The demand for cancer testing in Europe is expected to grow significantly in the coming years. Traditional cancer therapies generally involve treatment approaches that are non-partial toward cancer cells and can result in several serious side effects.
Quick and reliable sequencing of multiple genes simultaneously is possible using advanced profiling technologies such as next-generation sequencing (NGS). The use of advanced profiling technologies, such as NGS and PCR, is gaining traction in the treatment of cancer due to their high accuracy and declining testing costs. Furthermore, NGS has helped develop precision medicine, which involves tailoring treatments based on disease-causing molecular changes in a person's body. While NGS is used in various scenarios, oncologists use it to sequence their patients' biopsy samples to determine the right medicines that can target the genetic abnormalities driving tumor growth. Thus, the growing adoption of NGS and sequencing technologies for cancer diagnosis is further expected to drive market growth.
Click here to: Get Free Sample Pages of this Report
Biomarker testing provides insights into abnormalities in the DNA of the tumor or tissue and levels of specific proteins present in the tumor. Biomarker testing may show whether the cancer is more likely to grow and spread, whether certain cancer treatments are likely (or unlikely) to be helpful, whether the cancer treatment is working or not, and look for possible signs of cancer reoccurrence.
The growing adoption of NGS across the European region is further expected to aid in the adoption of precise cancer testing for better clinical outcomes. Several initiatives are being taken in this regard.
In 2021, Germany removed the prior authorization requirement for sequencing analysis by public health insurers. This resulted in better access to diagnostic approaches for the entire population. Also in 2021, Illumina, Inc. (U.S.), a leader in next-generation sequencing technology, announced an agreement with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen (Germany) to assess whole-genome sequencing (WGS) as a first-line diagnostic test for patients with genetic diseases and familial cancer syndromes. Such initiatives of adopting sequencing technologies for precision testing for cancer in Europe are further expected to generate significant opportunities for the players operating in the Europe cancer diagnostics market.
The large market share of the In Vitro Diagnostics segment is attributed to factors such as the technological advancements in IVD, the commercial availability of a diverse range of IVD reagents & consumables for the diagnosis of cancer, and the recurring use of IVD consumables.
IVD consumables are critical components in cancer diagnostics, allowing for reliable and precise examination of patient samples. They assist healthcare providers in obtaining vital information regarding genetic abnormalities, tumor markers, and other diagnostic indicators to monitor disease development, guide treatment decisions, and assess therapy responses in cancer patients.
The large market share of the Breast Cancer segment is attributed to the increase in breast cancer cases, government initiatives promoting breast cancer awareness regarding diagnosis and treatment, increasing healthcare expenditure, and inclusion of certain advanced technologies such as NGS in the reimbursement have propelled the demand for cancer diagnostics for breast cancer.
According to the GLOBOCAN, new breast cancer cases are estimated to increase from 557,532 in 2022 to 581,443 by 2030 in Europe. The mortality rate for this disease is estimated to increase from 144,439 in 2022 to 156,264 by 2030.
The large market share of the Hospitals & Diagnostic Laboratories segment is attributed to factors such as increasing cancer cases, higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, and the increasing number of hospitals and expansion of diagnostic laboratories.
Hospitals & diagnostic laboratories are the primary sources for patients to receive diagnoses and treatments for cancer. Thus, the inclination of patients is more toward hospitals & diagnostic laboratories. The clinical demand for mutation detection within multiple genes from a single tumor sample requires diagnostic laboratories to provide rapid, highly sensitive, high-throughput, accurate & parallel testing. Therefore, to meet this demand, many hospitals & diagnostic laboratories have adopted advanced technologies such as Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), Polymerase Chain Reaction (PCR), and Next-generation sequencing (NGS) as a standardized method for cancer diagnosis.
In 2024, Germany is expected to account for the largest share of the Europe cancer diagnostics market. Germany’s large share can be attributed to the high cancer incidence, the high adoption of advanced technologies, established healthcare systems, rising healthcare expenditures, increasing investments and funding for cancer research, initiatives to raise awareness about cancer diagnosis, and the presence of major market players in the region.
Due to the high incidence of cancer in Germany, there is a need to create awareness regarding its early diagnosis and treatment. These factors have led the German Federal Ministry of Education and Research (BMBF) and various stakeholders active in the field of cancer research to launch a joint initiative, namely the National Decade Against Cancer 2019–2029, to promote preventive measures, diagnostics, and therapies for cancer. Furthermore, the All.Can Germany initiative and DKTK – German Cancer Consortium are among the key notable projects of cancer care in the country.
The report includes a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments in leading industry market players over the past years. The key players operating in the Europe cancer diagnostics market include F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).
|
Particular |
Details |
|
Page No |
209 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
5.6% |
|
Market Size (Value) |
$12.21 billion by 2031 |
|
Segments Covered |
By Product
By Cancer Type
By End User
|
|
Countries Covered |
Europe (Germany, France, U.K., Spain, Italy, Switzerland, Netherlands, Rest of Europe) |
|
Key Companies |
F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.). |
The Europe cancer diagnostics market covers the market sizes & forecasts of offering, including product, cancer type, and end user. The Europe cancer diagnostics market studied in this report involves the value analysis of various segments and sub-segments of the Europe cancer diagnostics market at country levels.
The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% during the forecast period.
In 2024, the In Vitro Diagnostics segment is expected to account for the largest share of the Europe cancer diagnostics market.
The Breast Cancer segment is projected to create more traction in the Europe cancer diagnostics market.
The Europe cancer diagnostics market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Furthermore, supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.
The key players operating in the Europe cancer diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Laboratory Corporation of America Holdings (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), and Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan).
France, Germany, and the U.K. are projected to offer significant growth opportunities for the vendors in this market due to factors such as increasing cancer incidence, supporting government initiatives, rising healthcare expenditure, growing demand for precision oncology, and growing R&D investments for cancer.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Rising Cancer Prevalence Coupled with Technological Advancements Fueling the Market Growth
4.2.1.2. Supporting Initiatives for Early Cancer Diagnosis and Creating Awareness Driving the Market Growth
4.2.1.3. Growing Adoption and Supporting Initiatives for Precision Cancer Diagnostics Creating Opportunities for the Market Players
4.2.1.4. Insufficiencies in the Implementation of Cancer Screening Programs: A Challenge for Cancer Diagnosis in Europe
4.2.2. Factor Analysis
4.3. Trends
4.4. Regulatory Analysis
4.4.1. Regulatory Analysis for IVD Technologies
4.4.2. Regulatory Analysis for Diagnostic Imaging Devices
4.5. Porter’s Five Forces Analysis: Diagnostic Imaging Technologies for Cancer Screening
4.5.1. Bargaining Power of Buyers
4.5.2. Bargaining Power of Suppliers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
4.6. Porter’s Five Forces Analysis: IVD Technologies for Cancer Screening
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
4.7. Pricing Analysis
5. Europe Cancer Diagnostics Market–by Product
5.1. Overview
5.2. In Vitro Diagnostics
5.2.1. IVD Consumables
5.2.1.1. Kits & Assays
5.2.1.2. Reagents
5.2.2. IVD Instruments
5.2.2.1. Sequencers
5.2.2.2. Polymerase Chain Reaction (PCR) Systems
5.2.2.3. Immunoassay Analyzers
5.2.2.4. Microarray Readers
5.2.2.5. Other IVD Instruments
5.2.3. IVD Software & Services
5.3. Diagnostic Imaging
5.3.1. Imaging Instruments
5.3.1.1. Computed Tomography (CT)
5.3.1.2. Mammography
5.3.1.3. Magnetic Resonance Imaging (MRI)
5.3.1.4. Ultrasound
5.3.1.5. Other Imaging Instruments
5.3.2. Imaging Consumables
5.3.2.1. Contrast Agents
5.3.2.2. Syringes & Injectors
5.3.2.3. Contrast Delivery Systems
5.3.2.4. Skin Markers
5.3.2.5. Phantoms
5.3.2.6. Other Imaging Consumables
5.3.3. Imaging Software & Services
6. Europe Cancer Diagnostics Market–by Cancer Type
6.1. Overview
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Other Cancer Types
7. Europe Cancer Diagnostics Market–by End User
7.1. Overview
7.2. Hospitals & Diagnostic Laboratories
7.3. Diagnostic Imaging Centers
7.4. Pharmaceutical & Biotechnology Companies
7.5. Academic & Research Institutes
8. Europe Cancer Diagnostics Market Assessment— by Geography
8.1. Overview
8.2. Germany
8.3. France
8.4. U.K.
8.5. Italy
8.6. Spain
8.7. Switzerland
8.8. Netherlands
8.9. Rest of Europe (RoE)
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Market Share Analysis (2023)
9.4.1. Europe Cancer IVD Market Share Analysis (2023)
9.4.1.1. F. Hoffmann-La Roche Ltd (Switzerland)
9.4.1.2. Thermo Fisher Scientific Inc. (U.S.)
9.4.1.3. Illumina, Inc. (U.S.)
9.4.2. Europe Diagnostic Imaging Market Share Analysis (2023)
9.4.2.1. GE Healthcare Technologies Inc. (U.S.)
9.4.2.2. Siemens Healthineers AG (Germany)
9.4.2.3. Hologic, Inc. (U.S.)
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments, SWOT Analysis)
10.1. F. Hoffmann-La Roche Ltd
10.2. Thermo Fisher Scientific Inc.
10.3. QIAGEN N.V.
10.4. Abbott Laboratories
10.5. Illumina, Inc.
10.6. Siemens Healthineers AG
10.7. GE Healthcare Technologies Inc.
10.8. Hologic, Inc.
10.9. Koninklijke Philips N.V.
10.10. Fujifilm Holdings Corporation
10.11. Canon Medical Systems Corporation
(Note: SWOT Analysis of the Top 6 Companies Will Be Provided)
11. Appendix
11.1. Related Reports
List of Tables
Table 1 Europe: Single and Multi Biomarker Test Availability by Country, 2021
Table 2 Average Selling Prices: IVD Instruments
Table 3 Average Selling Prices: Diagnostic Imaging Instruments
Table 4 Europe Cancer Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 5 Europe Cancer In Vitro Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 6 Europe Cancer In Vitro Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Europe Cancer IVD Consumables Market, by Type, 2022–2031 (USD Million)
Table 8 Europe Cancer IVD Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 9 IVD Kits & Assays Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 10 IVD Reagents Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 11 Europe Cancer IVD Instruments Market, by Type, 2022–2031 (USD Million)
Table 12 Europe Cancer IVD Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Sequencers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 14 Polymerase Chain Reaction (PCR) Systems Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 15 Immunoassay Analyzers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 16 Microarray Readers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 17 Other IVD Instruments Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 18 Europe Cancer IVD Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Europe Imaging-Based Cancer Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 20 Europe Imaging-Based Cancer Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 21 Europe Cancer Diagnostic Imaging Instruments Market, by Type, 2022–2031 (USD Million)
Table 22 Europe Cancer Diagnostic Imaging Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Computed Tomography (CT) Scanners per 1,000,000 Inhabitants in European Countries (2021)
Table 24 CT Scanners Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 25 Mammography Machines per 1,000,000 Inhabitants in European Countries (2021)
Table 26 Mammography Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 27 Magnetic Resonance Imaging (MRI) Units per 1,000,000 Inhabitants in European Countries (2021)
Table 28 MRI Scanners Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 29 Ultrasound Scanners Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 30 Other Imaging Instruments Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 31 Europe Cancer Diagnostic Imaging Consumables Market, by Type, 2022–2031 (USD Million)
Table 32 Europe Cancer Diagnostic Imaging Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 33 Contrast Agents Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 34 Syringes & Injectors Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 35 Contrast Delivery Systems Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 36 Skin Markers Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 37 Phantoms Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 38 Other Imaging Consumables Market for Cancer Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 39 Europe Cancer Diagnostic Imaging Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 40 Europe Cancer Diagnostics Market, by Cancer Type, 2022–2031 (USD Million)
Table 41 Number of New Breast Cancer Cases in European Countries, 2022–2030
Table 42 Europe Cancer Diagnostics Market for Breast Cancer, by Country/Region, 2022–2031 (USD Million)
Table 43 Europe Cancer Diagnostics Market for Lung Cancer, by Country/Region, 2022–2031 (USD Million)
Table 44 Europe Cancer Diagnostics Market for Colorectal Cancer, by Country/Region, 2022–2031 (USD Million)
Table 45 Number Of New Prostate Cancer Cases In European Countries, 2022–2030
Table 46 Europe Cancer Diagnostics Market for Prostate Cancer, by Country/Region, 2022–2031 (USD Million)
Table 47 Number of Other Cancer Cases in European Countries, 2022–2030
Table 48 Europe Cancer Diagnostics Market for Other Cancer Types, by Country/Region, 2022–2031 (USD Million)
Table 49 Europe Cancer Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 50 Number of Hospitals in European Countries, 2021
Table 51 Europe Cancer Diagnostics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 52 Europe Cancer Diagnostics Market for Diagnostic Imaging Centers, by Country/Region, 2022–2031 (USD Million)
Table 53 Europe Cancer Diagnostics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 54 Europe Cancer Diagnostics Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 55 Europe: Cancer Diagnostics Market, by Country/Region, 2022—2031 (USD Million)
Table 56 Germany: Key Macro & Micro Indicators
Table 57 Germany: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 58 Germany: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 59 Germany: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 60 Germany: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 61 Germany: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 62 Germany: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 63 Germany: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 64 Germany: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 65 Germany: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 66 France: Healthcare Expenditure, 2017–2020 (USD Million)
Table 67 France: Key Macro & Micro Indicators
Table 68 France: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 69 France: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 70 France: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 71 France: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 72 France: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 73 France: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 74 France: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 75 France: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 76 France: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 77 U.K.: Key Macro & Micro Indicators
Table 78 U.K.: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 79 U.K.: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 80 U.K: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 81 U.K: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 82 U.K.: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 83 U.K.: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 84 U.K.: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 85 U.K.: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 86 U.K.: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 87 Italy: Key Macro & Micro Indicators
Table 88 Italy: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 89 Italy: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 90 Italy: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 91 Italy: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 92 Italy: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031(USD Million)
Table 93 Italy: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 94 Italy: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 95 Italy: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 96 Italy: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 97 Spain: Key Macro & Micro Indicators
Table 98 Spain: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 99 Spain: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 100 Spain: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 101 Spain: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 102 Spain: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 103 Spain: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 104 Spain: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 105 Spain: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 106 Spain: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 107 Switzerland: Key Macro & Micro Indicators
Table 108 Switzerland: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 109 Switzerland: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 110 Switzerland: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 111 Switzerland: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 112 Switzerland: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 113 Switzerland: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 114 Switzerland: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 115 Switzerland: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 116 Switzerland: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 117 Netherlands: Key Macro & Micro Indicators
Table 118 Netherlands: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 119 Netherlands: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 120 Netherlands: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 121 Netherlands: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 122 Netherlands: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 123 Netherlands: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 124 Netherlands: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 125 Netherlands: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 126 Netherlands: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 127 Rest Of Europe: Number Of New Cancer Cases, by Country, 2022 Vs. 2030
Table 128 Rest Of Europe: Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 129 Rest Of Europe: Cancer IVD Market, by Product, 2022—2031 (USD Million)
Table 130 Rest Of Europe: Cancer IVD Instruments Market, by Type, 2022—2031 (USD Million)
Table 131 Rest Of Europe: Cancer IVD Consumables Market, by Type, 2022—2031 (USD Million)
Table 132 Rest Of Europe: Imaging-Based Cancer Diagnostics Market, by Product, 2022—2031 (USD Million)
Table 133 Rest Of Europe: Cancer Diagnostic Imaging Instruments Market, by Type, 2022—2031 (USD Million)
Table 134 Rest Of Europe: Cancer Diagnostic Imaging Consumables Market, by Type, 2022—2031 (USD Million)
Table 135 Rest Of Europe: Cancer Diagnostics Market, by Cancer Type, 2022—2031 (USD Million)
Table 136 Rest Of Europe: Cancer Diagnostics Market, by End User, 2022—2031 (USD Million)
Table 137 Recent Developments, by Company, 2020-2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown Of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth for ecast Approach
Figure 7 Europe Cancer Diagnostics Market, by Product, 2024 VS. 2031 (USD Million)
Figure 8 Europe Cancer Diagnostics Market, by Cancer Type, 2024 VS. 2031 (USD Million)
Figure 9 Europe Cancer Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 10 Europe Cancer Diagnostics Market, by Country/Region
Figure 11 Impact Analysis of Market Dynamics
Figure 12 Europe: Estimated Number of New Cancer Cases 2020 VS. 2035
Figure 13 Eu Regulatory Pathway - IVDR 2017/746
Figure 14 Porter’s Five forces Analysis
Figure 15 Porter’s Five forces Analysis
Figure 16 Europe Cancer Diagnostics Market, by Product, 2024 VS. 2031 (USD Million)
Figure 17 Europe Cancer Diagnostics Market, by Cancer Type, 2024 VS. 2031 (USD Million)
Figure 18 Number of New Lung Cancer Cases in European Countries, 2022–2030
Figure 19 Number of New Colon Cancer Cases in European Countries, 2022–2030
Figure 20 Number of New Rectal Cancer Cases in European Countries, 2022–2030
Figure 21 Europe Cancer Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 22 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 23 Number of Cancer Cases in European Countries, 2022
Figure 24 Europe Cancer Diagnostics Market, by Country, 2024 Vs. 2031 (USD Million)
Figure 25 Europe Cancer Diagnostics Market: Regional Snapshot
Figure 26 Germany: Number of New Cancer Cases, 2022—2040
Figure 27 France: Number of New Cancer Cases, 2022—2040
Figure 28 U.K.: Number of New Cancer Cases, 2022—2040
Figure 29 Italy: Number of New Cancer Cases, 2022—2040
Figure 30 Italy: Number of Biotechnolgy Firms, 2010—2021
Figure 31 Spain: Healthcare Expenditure, 2017–2021 (USD Million)
Figure 32 Spain: Number of New Cancer Cases, 2022—2040
Figure 33 Switzerland: Number of New Cancer Cases, 2022—2040
Figure 34 Switzerland: Healthcare Expenditure, 2020–2024 (USD)
Figure 35 Netherlands: Number of New Cancer Cases, 2022—2040
Figure 36 Healthcare Expenditures In Belgium, Greece, Austria, and Poland, 2018-2021 (USD Million)
Figure 37 Key Growth Strategies Adopted by Leading Players, 2020– 2024
Figure 38 Europe Cancer In Vitro Diagnostics (IVD) Market: Competitive Benchmarking
Figure 39 Europe Cancer Diagnostic Imaging Market: Competitive Benchmarking
Figure 40 Europe Cancer In Vitro Diagnostics Market Share Analysis, by Key Players, 2023 (%)
Figure 41 Europe Cancer Diagnostics Market Share Analysis for Imaging, by Key Players, 2023 (%)
Figure 42 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2022)
Figure 43 Thermo Fisher Scientific Inc.: Financial Snapshot (2022)
Figure 44 QIAGEN N.V.: Financial Snapshot (2022)
Figure 45 Abbott Laboratories: Financial Snapshot (2022)
Figure 46 Illumina, Inc.: Financial Snapshot (2022)
Figure 47 Siemens Healthineers AG: Financial Snapshot (2023)
Figure 48 GE Healthcare Technologies Inc.: Financial Snapshot (2022)
Figure 49 Hologic, Inc.: Financial Snapshot (2023)
Figure 50 Koninklijke Philips N.V.: Financial Snapshot (2022)
Figure 51 Fujifilm Holdings Corporation: Financial Snapshot (2022)
Figure 52 Canon Medical Systems Corporation (A Subsidiary Of Canon Inc.): Financial Snapshot (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Jan-2024
Published Date: Jan-2024
Published Date: Nov-2023
Published Date: Sep-2023
Published Date: Sep-2023
